



Cristiana Sessa

Contact

Cristiana Sessa

Publications (12)

Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. *Lung Cancer* 2021; 156:91-99.

Jörger M, Sessa C, Stuedeli S, Levy N, Hafner P, Lane H, Larger P, Engelhardt M, Kaindl T, Volden M, Mark M, Mantiero M, Hess D, Metaxas Y, Stathis A, von Moos R. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors. *Invest New Drugs* 2019

Wicki A, Tzankov A, Hess V, Childs A, Hierro C, Rodón J, Hess D, Jörger M, von Moos R, Sessa C, Ritschard R, Prêtre V, Herrmann R, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Kristeleit R. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). *Eur J Cancer* 2018; 96:6-16.

Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. *Endocr Connect* 2017; 6:549-556.

Kunstfeld R, Moser E, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori F, Pfeilstöcker M, Raut C, Michielin O, Meran J, Lenz H, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer P, Markham M, Markman B, Mayerhoefer M, Remick S, Robson M, Rutkowski P, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber J, Wildiers H, Strasser F, Stiefel F, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll H, Schnipper L, Sessa C, Shapiro C, Steele J, Sternberg C, Yarden Y, Dittrich C, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close J, Coiffier B, Connolly R, Coupland S, Banerjee S, Awada A, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghier N, Lotz J, Österlund P, Pavlidis N, Purkalne G, De Petris L, De Santis M, de Vries E, Hahn S, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones D, Jost L, Keilholz U, Khan S, Kiss A, Grothey A, Gopalan P, Dizon D, Duff J, Duska L, Eniu A, Ernstoff M, Felip E, Fey M, Gilbert J, Girard N, Glaudemans A, Köhne C. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. *ESMO Open* 2016; 1:e000097.

Lennerz V, Woelfel T, Forssmann U, Zieschang J, Gnad-Vogt U, Ochsenbein A, Knuth A, von Boehmer L, Hess D, Boehm S, Mach N, Sessa C, Gallerani E, Gross S, Kaempgen E. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. *Cancer Immunol Immunother* 2014; 63:381-94.

Laurent J, Gnad-Vogt U, Stupp R, Quaratino S, Sessa C, Omelin A, Beck J, Gallerani E, Liedert B, Ongarello S, Bertrand C, Vicari M, Joffraud M, Gillessen Sommer S, Tourey C, Speiser D. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. *J Transl Med* 2013; 11:5.

Gallerani E, D'Incalci M, Sala F, Cereda R, Marsoni S, de Braud F, Driessen C, Böhm S, Martinelli G, Delmonte A, Hess U, Noberasco C, Marangon E, Brunelli D, Zucchetti M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. *Eur J Cancer* 2012; 49:290-6.

Gillessen S, Speiser D, Laurent J, Kramer D, Liedert B, Mattiacci M, Omelin A, Sessa C, Beck J, Gallerani E, Gnad-Vogt U, Stupp R. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. *Eur J Cancer* 2012; 49:35-44.

Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Köberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. *Oncology* 2011; 81:50-4.

Perotti A, Haluska F, Rivera V, Berk L, Corradino I, Marsoni S, Albalani J, Rojo F, Cresta S, Cerny T, Maur M, Capri G, Vigano L, Hess D, Sessa C, Locatelli A, Gianni L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. *J Clin Oncol* 2010; 28:4554-61.

Siano M, Gallino A, Sessa C, Mora O, Leoncini L, Oberson M, Rodriguez-Abreu D, Zucca E, Negretti L, Lerch E, Ghielmini M. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2008; 14:7935-9.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch